Drug intelligence / Profile preview

RPR131247

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules

Overview

RPR131247 is a synthetic small molecule classified as an alpha amino acid derivative. It was developed as an experimental compound and has not been approved for clinical use. Structurally, it has the chemical formula C19H19N5O4S2 and a molecular weight of approximately 445.5 g/mol[1][9]. RPR131247 is known to act as an inhibitor of serine proteases, specifically trypsin, based on crystallographic studies showing its complex with bovine trypsin[3][4]. The compound was investigated for its potential therapeutic applications but did not progress beyond preclinical or very early clinical development stages.

Targets

PRSS1 (Trypsin family)

Beyond the preview

Go deeper on RPR131247.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPR131247.

Explore the full profile